Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
LivaNova PLC (LIVN) is a global leader in medical technology innovation, specializing in life-supporting cardiopulmonary solutions and neuromodulation therapies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Track all official LivaNova press releases, earnings reports, and product development announcements in one centralized resource. Our curated news feed covers critical developments including FDA clearances, international expansion efforts, and partnerships shaping the future of cardiac surgery and neurological treatment technologies.
Key updates feature progress in extracorporeal circulation systems, enhancements to vagus nerve stimulation therapies, and sustainability initiatives across global manufacturing operations. The platform serves as a vital tool for monitoring how LivaNova’s innovations in heart-lung machines and depression treatment devices impact both patient outcomes and shareholder value.
Bookmark this page for immediate access to verified information about LIVN’s market position, intellectual property developments, and leadership changes. Stay informed about the medical technology pioneer driving advancements in critical care through its merged heritage of European and American engineering excellence.
LivaNova (Nasdaq: LIVN) will present eight scientific posters at the American Epilepsy Society Annual Meeting (Dec 5-9, 2025) showcasing real-world evidence from the CORE-VNS study and new health-economics analyses.
Key findings include median seizure reductions up to 95% for the most disabling seizure types at 36 months, early seizure improvements in children by 3 months with sustained benefit to 36 months, a 94% median reduction when VNS was used after 2–3 anti-seizure medications versus 57% after >10 medications, and a >70% decrease in rescue medication use at 36 months. Analyses also report reduced hospitalizations, ED visits and overall costs post-implantation across commercial, Medicare, and Medicaid cohorts.
LivaNova (Nasdaq: LIVN) appointed Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea, effective December 1, 2025. Blaise reports to Vladimir Makatsaria, CEO, and joins the Executive Leadership Team.
She brings more than 25 years in medtech and 19 years at ResMed with leadership roles in marketing, sales, strategy, and regional presidency across Europe. Her background includes board roles with MedTech Europe and the Medical Device Innovation Consortium. Blaise holds a bachelor’s in International Business from the University of Sheffield and an MBA from Kedge Business School.
LivaNova (Nasdaq: LIVN) said CFO Alex Shvartsburg will give a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City.
The presentation is scheduled for Tuesday, Dec. 2, 2025 at 1:30 PM ET, available live via webcast at www.livanova.com/events. Listeners are advised to log on about 10 minutes early. A replay will be posted on the LivaNova website within 24 hours after the live presentation.
LivaNova (Nasdaq: LIVN) announced that CMS assigned VNS Therapy for drug-resistant epilepsy to New Technology APC 1580 for new patient implants and moved end-of-service procedures to Level 5 APC, effective Jan. 1, 2026. CMS will increase hospital outpatient payments by about 48% for NPIs and 47% for EOS versus 2025 rates. LivaNova said the reimbursement change should improve hospital economics, reduce a barrier to procedure penetration, and expand patient access to VNS Therapy, which the company reports showed median seizure reductions of 80% and 95% in CORE-VNS at 36 months.
LivaNova (Nasdaq: LIVN) presented a strategic roadmap and 2030 financial targets at its 2025 Investor Day on November 12, 2025.
Key targets include high-single-digit-plus revenue CAGR to 2030, adjusted operating margin above 20% over the next three years and targeting high‑twenties by 2030, EPS CAGR in the low double digits to mid‑teens, and adjusted free cash flow conversion above 80%.
Growth pillars are maximizing Cardiopulmonary and Epilepsy cores, scaling Obstructive Sleep Apnea (OSA) with an independent U.S. commercial launch planned for 2027, and optional upside from Difficult‑to‑Treat Depression contingent on CMS coverage. OSA is projected to reach $200M–$400M revenue by 2030 and >25% adjusted operating margin, with break‑even expected by 2029.
LivaNova (Nasdaq: LIVN) reported Q3 2025 revenue of $357.8M, up 12.5% reported, 11.0% constant-currency and 12.5% organic versus prior year. Cardiopulmonary revenue rose 18.0% driven by Essenz perfusion system sales and consumables; Neuromodulation rose 6.9%. U.S. GAAP diluted EPS was $0.49; adjusted diluted EPS was $1.11. Adjusted operating income increased to $80.4M from $63.6M; operating cash flow was $85.1M and adjusted free cash flow was $62.0M. The company raised full‑year 2025 guidance: revenue growth to 8.5%–9.5% (constant currency), adjusted EPS to $3.80–$3.90, and adjusted free cash flow to $160M–$180M. Essenz commercial launch initiated in China and a new director was appointed.
LivaNova (Nasdaq: LIVN) will present a general business update at the Wolfe Research Healthcare Conference in New York on Mon., Nov. 17, 2025 at 2:40 p.m. ET.
Chief Executive Officer Vladimir Makatsaria and Chief Financial Officer Alex Shvartsburg will take part in a fireside chat. The live webcast is open to registered viewers via www.livanova.com/events, with attendees advised to log on ~10 minutes early. A replay will be posted on the LivaNova website within 24 hours after the live presentation.
LivaNova (Nasdaq: LIVN) will release its third-quarter 2025 results prior to a conference call on Wednesday, Nov. 5, 2025 at 1:00 p.m. London time (8:00 a.m. ET). The company will host an audiocast of the call at www.livanova.com/events and recommends logging on about 10 minutes early to confirm setup. Telephone access: +1 833 470 1428 (U.S.) or +1 929 526 1599 (outside U.S.) using access code 817099. A replay will be posted in the Investors section of the LivaNova website immediately after the event.
LivaNova (Nasdaq: LIVN) will present scientific data at the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis on Oct 9–10, 2025. Presentations include a five‑year analysis of the THN‑3 randomized controlled trial and 12‑month top‑line data from the OSPREY follow‑on RCT. OSPREY reported a 65% responder rate at 12 months (≥50% AHI improvement and AHI <20). The company will also host a breakfast symposium on Oct 9 and feature an oral presentation and poster describing proximal hypoglossal nerve stimulation (p‑HGNS) therapy and the aura6000 System.
Presenters include Dr. Alan Schwartz, Dr. Ofer Jacobowitz, and Dr. Atul Malhotra.
LivaNova (Nasdaq: LIVN) has appointed Donald (Don) Zurbay to its Board of Directors, where he will serve on the Audit and Compliance Committee. Zurbay brings over 30 years of experience in finance, accounting, and strategy, most recently serving as President and CEO of Patterson Companies after being its CFO. He previously spent nearly 13 years at St. Jude Medical in various leadership roles, including CFO.
Zurbay currently serves on the Board of Directors at Sight Sciences, chairing its Audit Committee. He holds a bachelor's degree in business accounting from the University of Minnesota. With this appointment, the LivaNova Board now comprises 11 Directors.
FAQ
What is the current stock price of Livanova Plc (LIVN)?
What is the market cap of Livanova Plc (LIVN)?
